Log in

Evolus Stock Forecast, Price & News

+0.03 (+0.78 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $3.87
50-Day Range
MA: $3.62
52-Week Range
Now: $3.87
Volume298,527 shs
Average Volume372,052 shs
Market Capitalization$130.61 million
P/E RatioN/A
Dividend YieldN/A
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.
Read More
Evolus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EOLS



Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share


Net Income$-90,030,000.00
Net Margins-161.74%


Market Cap$130.61 million
Next Earnings Date11/2/2020 (Estimated)
+0.03 (+0.78 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evolus (NASDAQ:EOLS) Frequently Asked Questions

How has Evolus' stock been impacted by COVID-19?

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EOLS shares have decreased by 34.5% and is now trading at $3.87.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Evolus?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Evolus

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Evolus

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.75) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.03. The business had revenue of $10.50 million for the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative net margin of 161.74% and a negative return on equity of 162.50%.
View Evolus' earnings history

What price target have analysts set for EOLS?

7 brokers have issued 12-month price targets for Evolus' stock. Their forecasts range from $3.00 to $25.00. On average, they anticipate Evolus' stock price to reach $9.43 in the next year. This suggests a possible upside of 143.6% from the stock's current price.
View analysts' price targets for Evolus

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Laidlaw Wealth Management LLC (2.51%), Alyeska Investment Group L.P. (0.99%), Bank of New York Mellon Corp (0.25%), Nuveen Asset Management LLC (0.21%), Virtu Financial LLC (0.21%) and UBS Group AG (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus

Which major investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for Evolus

Which major investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Laidlaw Wealth Management LLC, Virtu Financial LLC, Alyeska Investment Group L.P., Jefferies Group LLC, Laidlaw Wealth Management LLC, PDT Partners LLC, Advisor Group Holdings Inc., and Algert Global LLC. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $3.87.

How big of a company is Evolus?

Evolus has a market capitalization of $130.61 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.